Nancy Simonian joins board of Seattle Genetics

Nancy Simonian, former chief medical officer at Takeda subsidiary Millennium, has been appointed to the board of US biotech Seattle Genetics.

She spent ten years at Millennium from 2001 to 2011, leading clinical and regulatory activities, working on such product approvals as Velcade.

For the past year, she has worked as an independent consultant to the biotech industry.

“Nancy brings significant experience in all aspects of clinical development, regulatory affairs and medical research, as well as program management and strategic prioritization of product portfolios,” said Dr Clay Siegall, president and CEO of Seattle Genetics.

“She is a valuable addition to our Board as we continue executing on our broad clinical development program for Adcetris and advancing our pipeline of clinical and preclinical products aimed at improving treatments for people with cancer.”

Prior to her time at Millennium, Simonian was VP of clinical research at Biogen, as well as assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School.

She said of her appointment: “I look forward to working with the Board and the management team to maximise the potential of Seattle Genetics' antibody-drug conjugate technology, collaborations and value to patients.”